Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement
Journal of Clinical Medicine · 21.11.2023 · 12 (23) · 7199
DOI: 10.3390/jcm12237199 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.11.2023. Verfasst von Steffen Mitzner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division for Tropical Medicine, Infectious Diseases and Nephrology, Department of Internal Medicine, University of Rostock, 18051 Rostock, Germany. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CytoSorbents Europe GmbH, CytoSorbents Inc. US Monmouth Junction, NJ, USA.
Abstract (Originalsprache)
A dysregulated host response is a common feature in critically ill patients due to both infectious and non-infectious origins that can lead to life-threatening organ dysfunction, which is still the primary cause of death in intensive care units worldwide. In its course, pathologic, unregulated levels of inflammatory mediators are often released into the circulation, a phenomenon also referred to as a “cytokine storm”. To date, there are no approved therapies to modulate the excessive immune response and limit hyperinflammation with the goal of preventing related organ failure and death. In this context, extracorporeal blood purification therapies aiming at the alteration of the host inflammatory response through broad-spectrum, non-selective removal of inflammatory mediators have come into focus. A novel hemoadsorption device (CytoSorb®, CytoSorbents Inc., Princeton, NJ, USA) has shown promising results in patients with hyperinflammation from various origins. Although a significant body of literature exists, there is ongoing research to address many important remaining questions, including the optimal selection of patient groups who might benefit the most, optimal timing for therapy initiation, optimal schedule for adsorber exchanges and therapy duration, as well as an investigation into the potential removal of concomitant antibiotics and other medications. In this review, we discuss the existing evidence and provide a consensus-based best practice guidance for CytoSorb® hemoadsorption therapy in patients with vasoplegic shock.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division for Tropical Medicine, Infectious Diseases and Nephrology, Department of Internal Medicine, University of Rostock, 18051 Rostock, Germany.
- Department of Anesthesiology and Intensive Care Medicine, Klinikum Leer, 26789 Leer, Germany.
- Department of Intensive Care, Erasmus MC, University Medical Centre Rotterdam, 3015 GD Rotterdam, The Netherlands.
- Department of Anesthesiology and Intensive Care Medicine, Semmelweis University, 1085 Budapest, Hungary.
- CytoSorbents Europe GmbH, 12587 Berlin, Germany.
- SODIR Research Group, Intensive Care Department, Vall d'Hebron University Hospital, Vall d'Hebron Institut de Recerca, 08035 Barcelona, Spain.
ORCID-Profile: Klaus Kogelmann, Zsolt Molnár, Ricard Ferrer, Axel Nierhaus
Förderung
- CytoSorbents Europe GmbH
- CytoSorbents Inc. US Monmouth Junction, NJ, USA
Zitieren
APA
Mitzner, S., Kogelmann, K., Ince, C., Molnár, Z., Ferrer, R., & Nierhaus, A. (2023). Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement. Journal of Clinical Medicine, 12(23), 7199. https://doi.org/10.3390/jcm12237199
Vancouver
Mitzner S, Kogelmann K, Ince C, Molnár Z, Ferrer R, Nierhaus A. Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement. Journal of Clinical Medicine. 2023;12(23):7199. doi:10.3390/jcm12237199
BibTeX
@article{Mitzner2023,
author = {Mitzner, Steffen and Kogelmann, Klaus and Ince, Can and Molnár, Zsolt and Ferrer, Ricard and Nierhaus, Axel},
title = {Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {23},
pages = {7199},
doi = {10.3390/jcm12237199}
}
EUVIMED